Yahoo Finance • 2 months ago
We recently compiled a list of the 15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers.In this article, we are going to take a look at where Immunocore Holdings plc (NASDAQ:IMCR) stands against the other Worst 52-Week Low Sto... Full story
Yahoo Finance • 2 months ago
We recently published a list of 15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers. In this article, we are going to take a look at where Immunocore Holdings plc (NASDAQ:IMCR) stands against the other worst 52-week low stock... Full story
Yahoo Finance • 5 months ago
Immunocore Holdings plc Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma The Phase 3 PR... Full story
Yahoo Finance • 11 months ago
Key Insights The projected fair value for Immunocore Holdings is US$136 based on 2 Stage Free Cash Flow to Equity Immunocore Holdings is estimated to be 50% undervalued based on current share price of US$68.32 Analyst price target for IMC... Full story
Yahoo Finance • 12 months ago
Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology compan... Full story
Yahoo Finance • last year
In this piece, we will take a look at the 11 best undervalued U.K. stocks to buy now. If you want to skip our overview of the British economy, then take a look at 5 Best Undervalued UK Stocks To Buy Now. The U.K. is one of the biggest eco... Full story
Yahoo Finance • last year
Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of £49.7 million ($60.7 million) in Q3 2023, maintaining strong momentum in major markets with continued reimbursement expansion gl... Full story
Yahoo Finance • last year
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, 01 November 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific... Full story
Yahoo Finance • last year
Data published in New England Journal of Medicine and presented as a late breaking abstract in mini oral session at ESMO Congress 2023 KIMMTRAK demonstrated long-term survival benefit in HLA-A*02:01 positive patients with previously untre... Full story
Yahoo Finance • last year
Immunocore announces upcoming presentation and posters at ESMO 2023 Long-term survival data for KIMMTRAK in previously untreated patients with metastatic uveal melanoma to be presented as a late-breaking abstract in a mini oral session (... Full story
Yahoo Finance • last year
In this article, we will take a look at the 10 stocks receiving a massive vote of approval from Wall Street analysts. If you want to see some more stocks on the list, go directly to 5 Stocks Receiving a Massive Vote of Approval From Wall S... Full story
Yahoo Finance • last year
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 01 September 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the de... Full story
Yahoo Finance • 2 years ago
Immunocore Holdings (NASDAQ:IMCR) First Quarter 2023 Results Key Financial Results Revenue: UK£44.5m (up 98% from 1Q 2022). Net loss: UK£16.7m (loss widened by 3.5% from 1Q 2022). UK£0.35 loss per share. earnings-and-revenue-growth All... Full story
Yahoo Finance • 2 years ago
Immunocore Reports First Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of £42.1million ($52. million) in Q12023, with continued commercial expansion Randomization started in Phase 2/3 trial with KIMMTR... Full story
Yahoo Finance • 2 years ago
Immunocore to present at the Bank of America Securities 2023Health Care Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 03 May 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology com... Full story
Yahoo Finance • 2 years ago
Immunocore presentsnew KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival In the Phase 3 trial, early on-treatmentctDNA reduction was strongly associated with longer overall survival (OS) Media... Full story
Yahoo Finance • 2 years ago
Immunocore to present at the 22nd Annual Needham Virtual Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 April 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology compa... Full story
Yahoo Finance • 2 years ago
Immunocore to present four posters at AACR Annual Meeting 2023 Updatedthree-year overall survival data for tebentafusp-tebn in previously treated metastatic uveal melanoma Phase 3 data showing early ctDNA reduction on tebentafusp-tebn as... Full story
Yahoo Finance • 2 years ago
Immunocore Reports 2022 Financial Results and Provides Business Update KIMMTRAK / tebentafusp net revenues of £42million ($51million) in Q4 2022 and£117 million ($141million)in 2022; approved in over 30 countries and nearly 200 patients o... Full story
Yahoo Finance • 2 years ago
Immunocore to Report Fourth Quarter and Full Year 2022 Earnings and Host Call on March 1, 2023 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 23 February, 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage... Full story